Updated: 5 days ago
Medically reviewed by Dr. Wang
Key Takeaways |
|
Introduction
CAR-T for solid tumors has reached an approval milestone in China for a defined group of gastric and gastroesophageal junction cancers, but it is not a general treatment for all solid cancers. Liver and brain cancer examples remain research pathways, while related cell therapies have their own approvals for selected melanoma and synovial sarcoma patients. The useful question is not simply “Does CAR-T work?” but “Which product, for which cancer, under which indication or study?”
Why Has CAR-T Worked for Blood Cancer but Not Solid Tumours?
CAR-T has faced additional obstacles in solid tumours: finding a safe target, getting cells into the tumour and keeping them active once there. A solid tumour is not simply a blood cancer in a different location.
Chimeric antigen receptor T-cell therapy, or CAR-T, adds an engineered receptor to immune cells called T cells. This receptor is designed to recognize a chosen surface target. Established blood-cancer applications include selected leukemias, lymphomas and multiple myeloma.
Solid cancers can contain cells with different target expression. A target may also occur on healthy tissue, making specificity a safety concern. Dense tissue and the tumour's surrounding environment can impede immune cells or weaken their activity. Researchers are testing different targets, cell designs and delivery approaches to address these problems.
These barriers explain why success in one cancer cannot establish that the same CAR-T product will work in a different solid tumour.
Table of Content
What Changed in 2026?
The milestone was a specific gastric-cancer CAR-T approval in China, rather than approval of the entire approach for every solid tumour. Government reporting identifies satricabtagene autoleucel, or satri-cel, as the first CAR-T approved for a solid tumour.
Its reported indication requires CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastroesophageal junction adenocarcinoma, with progression after previous treatment as specified in the table below. CLDN18.2 is a protein target; HER2 is another tumour biomarker. “Positive” or “negative” results must be interpreted using the product's criteria.
The randomized CT041-ST-01 trial, published by Qi and colleagues in The Lancet, compared satri-cel with treatment selected by physicians. It was a stronger comparative test than an uncontrolled early study, but its result remains specific to the selected gastric/GEJ population.
Milestone or evidence | Verified finding | What it does not establish |
Satri-cel Chinese approval, government reporting | Approval reported as 22 June 2026; CLDN18.2-positive, HER2-negative unresectable advanced gastric/GEJ adenocarcinoma after progression on at least two prior lines | Approval for other solid tumours, automatic international access, or approval in the reader's home country |
CT041-ST-01, Lancet 2025 | First randomized CAR-T trial in a solid tumour, according to the paper; open-label phase II, 156 participants | A large phase III study of every solid cancer |
CT041-ST-01 efficacy | Median progression-free survival: 3.25 months with satri-cel vs 1.77 months with physician's choice; HR 0.37, 95% CI 0.24–0.56 | Overall survival, cure or an individual patient's likely result |
Progression-free survival measures time before disease worsening or death; it is not the same as overall survival. The findings support a treatment discussion for the studied group, not a promise that the cancer will respond. [4]
Which Solid Tumours Are Being Studied?
Different solid tumours are being studied with different CAR-T targets and designs. Their status should be read product by product, rather than treating “CAR-T for solid tumors” as one medicine.
A Plain-Language Status Board
Status | Cancer and approach | What families should understand |
Approved in a defined jurisdiction | Satri-cel for the specified gastric/GEJ population in China | Verify the current label and individual eligibility; the diagnosis alone is insufficient |
Comparative/pivotal trial evidence | CT041-ST-01 gastric/GEJ study | Published phase II randomized evidence supported the satri-cel pathway; this particular study was closed to new patients, not a current recruitment offer |
Early clinical research | GD2-CART01 for relapsed/refractory high-risk neuroblastoma | Early phase I–II research; reported activity does not establish routine approval |
Early clinical research | GD2 CAR-T for selected H3K27M-mutated diffuse midline gliomas | Small phase I study with tumour reductions and neurological improvements in some participants; specialized neurotoxicity monitoring was needed |
Early clinical research | GPC3-targeting CAR-T for hepatocellular carcinoma and other GPC3-expressing tumours; NCT05003895 | Phase I safety/feasibility research, not an approved liver-cancer treatment |
Laboratory/preclinical research | Additional engineered T-cell strategies studied in mouse models | Animal findings do not establish benefit or safety in patients |
About “late-stage”: The gastric study is described here as randomized/pivotal phase II, preserving its actual design. It should not be relabelled phase III. The examples in this board are selected research pathways, not a complete global trial inventory.
Can CAR-T Treat Liver Cancer Yet?
GPC3-directed CAR-T is being investigated for hepatocellular carcinoma, but this article does not identify an approved GPC3 CAR-T liver-cancer product. The NCI record for NCT05003895 describes a phase I study assessing safety and feasibility.
GPC3 stands for glypican-3, a target being assessed in tumour tissue. A suitable target is only part of eligibility: pathology, earlier treatment and organ function also matter. Ask for the registration number and current site-level recruitment status; an “active” listing does not guarantee a screening place.
What About Neuroblastoma and Brain Tumours?
GD2 CAR-T has shown early activity, but the studies are not evidence of routine treatment for all childhood or brain cancers. GD2 is the target used in these particular approaches.
The diffuse midline glioma study's publication dates need care: it appeared online in late 2024 and in a 2025 Nature issue. Participants had a specific molecular diagnosis, and the investigators noted that patient selection complicated interpretation of survival. Tumour reduction in some participants cannot be converted into a general survival or cure claim.
What Other Cell Therapies Are Approved for Solid Tumours?
Some related cell therapies are approved for selected solid cancers, but they are not CAR-T. Confusing them can make a news headline sound broader than its actual indication.
Approach | How it works, in plain language | Example and regulatory scope |
CAR-T | T cells receive an engineered receptor recognizing a chosen surface target | Satri-cel's reported Chinese gastric/GEJ indication |
TIL: tumour-infiltrating lymphocyte therapy | Immune cells already present in tumour tissue are expanded for treatment | Lifileucel received FDA accelerated approval on 16 February 2024 for adults with unresectable/metastatic melanoma after a PD-1 blocker and, if BRAF V600-positive, appropriate BRAF-targeted treatment |
TCR-T: T-cell receptor-engineered therapy | T cells receive a receptor recognizing a target presented through a compatible HLA molecule | Afamitresgene autoleucel's original FDA accelerated-approval announcement was 2 August 2024 for selected adults with synovial sarcoma; the FDA product record lists an original approval letter dated 1 August 2024 |
Current Tecelra indication | TCR-T requires both matching HLA type and MAGE-A4 tumour expression | FDA prescribing information revised June 2026 includes adults and patients aged 12 and older after prior chemotherapy; qualifying HLA-A*02 subtypes and MAGE-A4 testing remain required |
HLA means human leukocyte antigen, part of the body's system for presenting targets to T cells. A synovial sarcoma diagnosis alone does not establish eligibility for TCR-T.
The current Tecelra label also removes the accelerated-approval statement that appeared in the earlier indication. That is why the table distinguishes the original announcement from current prescribing information. Lifileucel's original accelerated approval and the gastric CAR-T milestone should likewise be described in their own jurisdiction and disease setting.
What Are the Risks?
Cell therapies can cause serious adverse effects and require a product-specific safety discussion. Being made from a person's own cells does not make treatment harmless.
Risks and Side Effects
CAR-T can cause cytokine release syndrome, an inflammatory reaction that may lead to fever, low blood pressure or breathing problems. Neurological toxicity and infection are also recognized concerns. Damage to healthy tissue sharing the target is another safety issue.
Brain-tumour CAR-T requires special caution: the published GD2 study reported inflammation-associated neurotoxicity and intensive monitoring. Its care requirements should not be generalized from a routine infusion appointment.
Related therapies have distinct risks. Lifileucel's FDA information includes warnings about treatment-related death, severe blood-count suppression, infections and cardiopulmonary or kidney impairment. Tecelra's current label warns about potentially severe cytokine release syndrome, neurological toxicity, low blood counts and infection.
When Should We Talk to Our Doctor?
Bring the treatment name or trial number to your oncologist before changing care or arranging travel. Ask whether the news concerns your exact diagnosis and whether the option is approved for that situation, investigational, or supported only by laboratory findings.
Useful questions include:
Which tissue tests and clinical information would establish relevance?
What treatment alternatives are available locally?
If this is research, what are the study phase, current recruitment status and unknowns?
What happens during screening or manufacturing, and what care is needed meanwhile?
Who handles complications and follow-up after returning home?
After cell therapy, follow the treating team's emergency plan. Fever, difficulty breathing, new confusion or worsening neurological symptoms need prompt medical assessment; severe symptoms should not wait for an online consultation.
For readers in Southeast Asia, Australia and New Zealand, local authorization and funding need separate checks. A foreign approval is evidence about that regulator's decision, not proof of local coverage or international patient admission.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Is CAR-T Approved for Solid Tumors?
Yes, for a defined gastric and gastroesophageal junction cancer indication in China, according to government reporting of satri-cel's approval. This does not mean CAR-T is approved for every solid tumour or in every country. Verify the product, indication and individual eligibility with the treating team.
Can CAR-T Treat Liver Cancer?
GPC3-targeting CAR-T is being studied for hepatocellular carcinoma. NCT05003895 is a phase I safety and feasibility study, not evidence of an approved liver-cancer CAR-T product. Ask your oncologist whether a specific trial fits the diagnosis and whether its site is currently screening patients.
What Is the Difference Between CAR-T and TIL Therapy?
CAR-T adds an engineered receptor to T cells so they recognize a chosen surface target. TIL therapy expands immune cells collected from tumour tissue. Both are forms of cell therapy, but their products, indications and safety requirements differ; TIL approval for melanoma does not establish CAR-T approval for melanoma.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
Sources
National Cancer Institute. CAR T Cells: Engineering Immune Cells to Treat Cancer. Updated 26 February 2025. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
Shanghai Pudong New Area Government. Pudong company's world-first solid tumor CAR-T therapy approved in China. 24 June 2026. https://english.pudong.gov.cn/2026-06/24/c_1192878.htm
Science and Technology Commission of Shanghai Municipality. 全球首款实体瘤CAR-T疗法获批上市. 23 June 2026. https://stcsm.sh.gov.cn/xwzx/mtjj/20260623/b967b22329f24849949649988dd12897.html
Qi C et al. CT041-ST-01: a randomised, open-label, phase 2 trial. Lancet. Online 31 May 2025; issue 7 June 2025;405:2049–2060. DOI 10.1016/S0140-6736(25)00860-8. Abstract read earlier in this working session. https://pubmed.ncbi.nlm.nih.gov/40460847/
FDA. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. 16 February 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma
FDA. FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma. 2 August 2024 announcement. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma
Monje M et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. Online 13 November 2024;637:708–715 (2025). DOI 10.1038/s41586-024-08171-9. https://www.nature.com/articles/s41586-024-08171-9
National Cancer Institute. Stealing Strategies from Cancerous T Cells May Boost Immunotherapy. 20 March 2024. https://www.cancer.gov/news-events/cancer-currents-blog/2024/gene-alteration-boosts-t-cell-therapy
Del Bufalo F et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. NEJM. 6 April 2023;388:1284–1295. DOI 10.1056/NEJMoa2210859. Direct full-text fetch blocked; indexed journal text and reference in source 7 located. No numerical response claim is made here. https://www.nejm.org/doi/full/10.1056/NEJMoa2210859
NCI. GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies. NCT05003895; update date not displayed in retrieved record. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT05003895&r=1 ; registry https://clinicaltrials.gov/study/NCT05003895
National Cancer Institute. T-cell Transfer Therapy. Updated 5 August 2024. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy
FDA. TECELRA product page. Undated page; supporting approval letters dated 1 August 2024 and 17 June 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecelra
FDA. TECELRA prescribing information. Revised June 2026. https://www.fda.gov/media/180565/download
